Business
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the A...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Nov. 14, 2019\n\n\n\nKey Opinion Leaders Will Provide Updated Results on Efficacy, Safety and Delivery of MDNA55\n TORONTO and HOUSTON, Nov. 14, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that key opinion leaders, Dr. Sampson and Dr. Butowski, will present updated results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (\"rGBM\") at the 24th Annual Meeting of the Society of Neuro-Oncology (\"SNO\") and 3rd Joint Conference of SNO and Society for CNS Interstitial Delivery of Therapeutics (\"SNO-SCIDOT\") to be held from November 20 to 24 at the JW Marriott Desert Ridge Resort in Phoenix, Arizona.\nThe oral presentations will provide an update on efficacy, safety and data from the MDNA55 Phase 2b clinical trial in patients with rGBM, the most common and deadly form of brain cancer. \nDetails of the presentations are as follows:\nPresenter: Dr. Nicholas Butowski, MD – Professor of Neurological Surgery and Director of Translational Research in Neuro-Oncology at The Helen Diller Family Comprehensive Cancer Center, University of California San FranciscoTitle: Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent GlioblastomaDate/Time: Wednesday, November 20, 2019 at 3:10 PM MTRoom: Grand Saguaro East\nPresenter: Dr. John Sampson, MD, PhD, MHSc, MBA - Robert and Gloria Wilkins Distinguished Professor and Chair of Neurosurgery, Department of Neurosurgery, Duke University School of MedicineTitle: Combating Recurrent Glioblastoma with MDNA55, an Interleukin-4 Receptor Targeted Immunotherapy, Through MRI-Guided Convective DeliveryDate/Time: Sunday, November 24, 2019 at 9:45...